Alnylam Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing RNA interference (RNAi) therapeutics. This innovative gene silencing technology targets the root ca... Alnylam Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing RNA interference (RNAi) therapeutics. This innovative gene silencing technology targets the root causes of diseases at the genetic level, offering potential treatments for rare and prevalent conditions across multiple therapeutic areas. The company specializes in creating transformational medicines that address unmet medical needs in sectors such as rare diseases, cardiometabolic disorders, and other genetic conditions. Alnylam Pharmaceuticals Inc advances a pipeline of investigational RNAi therapeutics designed for subcutaneous or intravenous administration, emphasizing precision medicine approaches. Its products and programs primarily serve patients worldwide through partnerships with healthcare providers and regulatory pathways. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals Inc plays a significant role in the biotechnology sector by pioneering RNAi as a novel modality for disease modification and management.Show lessShow more

Disclosures ESG Data Financial Data

Income Statement Balance Sheet Group Entities

Data not available

Financial Fundamentals data not yet covered for Alnylam Pharmaceuticals

We have not yet reviewed Alnylam Pharmaceuticals's disclosures for Financial Fundamentals data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Alnylam Pharmaceuticals's data?

Start your 30-day free trial to request a data review for Alnylam Pharmaceuticals.

Start Free Trial

Legal Center Contact Us

Alnylam Pharmaceuticals Inc

Financial Fundamentals data not yet covered for Alnylam Pharmaceuticals

Account Restricted